GeneDx and Partners Secure $14.4M NIH Grant to Launch First U.S. Multi-State Genomic Newborn Screening Initiative
**GeneDx Holdings Corp. and Partners Launch First U.S. National Genomic Newborn Screening Initiative with $14.4 Million NIH Grant** GeneDx Holdings Corp. (Nasdaq: WGS) has announced the launch of BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), the nation's first multi-state genomic newborn screening initiative. The project is funded by a $14.4 million grant from the National Institutes of Health (NIH) Common Fund Venture Program, awarded jointly to multiple organizations including Mass General Brigham, Ariadne Labs, Boston Children's Hospital, Albert Einstein College of Medicine, the Association of Public Health Laboratories (APHL), Case Western Reserve University, Baylor College of Medicine, and Illumina. BEACONS will pilot the integration of whole genome sequencing into state newborn screening programs, recruiting up to 30,000 newborns across as many as 10 states over the next three years. This collaboration aims to evaluate the feasibility, ethical considerations, and potential public health impact of using genomic sequencing for newborn screening in the United States. If successful, the project could pave the way for expanding genomic screening nationwide.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251001487540) on October 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.